A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group

Autor:	G A, Dijkman, F M, Debruyne, P, Fernandez del Moral, J W, Plasman, J W, Hoefakker, J G, Idema, M, Sykes
Rok vydání:	1994
Předmět:	Male Delayed-Action Preparations Injections Subcutaneous Goserelin Humans Prostatic Neoplasms Drug Administration Schedule
Zdroj:	European urology. 26
ISSN:	0302-2838
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::3373ec370f73500f288df9f2793df9c2 https://pubmed.ncbi.nlm.nih.gov/7737253 Zobrazit plný text záznamu